Carcinoembryonic antigen and carbohydrate antigen 19-9 are prognostic predictors of colorectal cancer with unresectable liver metastasis

Oncology Letters

Volumn 3, Issue 4, 2012, Pages 767-771

  Mitsuyama, Yoshinobu ^a   Shiba, Hiroaki ^a   Haruki, Koichiro ^a   Fujiwara, Yuki ^a   Furukawa, Kenei ^a   Iida, Tomonori ^a   Hayashi, Takenori ^a   Ogawa, Masaichi ^a   Ishida, Yuichi ^a   Misawa, Takeyuki ^a   Kashiwagi, Hideyuki ^a   Yanaga, Katsuhiko ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Carbohydrate antigen 19 9; Carcicoembryonic antigen; Colorectal cancer; Liver metastasis; Prognosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; FEMALE; HUMAN; LIVER METASTASIS; MALE; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY;

EID: 84856930743     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.574     Document Type: Article

References (36)

1. Weitz J, Koch M, Debus J, Höhler T, Galle PR and Büchler MW: Colorectal cancer. Lancet 365: 153-65, 2005.
2. O'Reilly DA and Poston GJ: Colorectal liver metastases: current and future perspectives. Future Oncol 2: 525-531, 2006.
3. Rodgers MS and McCall JL: Surgery for colorectal liver metastases with hepatic lymph node involvement: a systematic review. Br J Surg 87: 1142-1155, 2000.
4. Martin LW and Warren RS: Current management of colorectal liver metastases. Surg Oncol Clin N Am 9: 853-876, 2000.
5. Penna C and Nordlinger B: Colorectal metastasis (liver and lung). Surg Clin North Am 82: 1075-1090, 2002.
6. Kato T, Yasui K, Hirai T, Kanemitsu Y, Mori T, Sugihara K, Mochizuki H, and Yamamoto J: Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum 46: S22-S31, 2003.
7. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P and Jaeck D: Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Cancer 77: 1254-1262, 1996.
8. Seifert JK, Böttger TC, Weigel TF, Gönner U and Junginger T: Prognostic factors following liver resection for hepatic metastases from colorectal cancer. Hepatogastroenterology 47: 239-246, 2000.
9. Fong Y, Fortner J, Sun RL, Brennan MF and Blumgart LH: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230: 309-321, 1999.
10. Minagawa M, Makuuchi M, Torzilli G, Takayama T, Kawasaki S, Kosuge T, Yamamoto J and Imamura H: Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg 231: 487-499, 2000.
11. Jonas S, Thelen A, Benckert C, Spinelli A, Sammain S, Neumann U, Rudolph B and Neuhaus P: Extended resections of liver metastases from colorectal cancer. World J Surg 31: 511-521, 2007.
12. Jaeck D, Oussoultzoglou E, Rosso E, Greget M, Weber JC and Bachellier P: A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg 240: 1037-1049, 2004.
13. Wood CB, Gillis CR and Blumgart LH: A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol 2: 285-288, 1976.
14. Wagner JS, Adson MA, Van Heerden JA, Adson MH and Ilstrup DM: The natural history of hepatic metastases from colorectal cancer: a comparison with resective treatment. Ann Surg 199: 502-508, 1984.
15. Wanebo HJ, Rao B, Pinsky CM, Hoffman RG, Stearns M, Schwartz MK and Oettgen HF: Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med 299: 448-451, 1978.
16. Moertel CG, O'Fallon JR, Go VL, O'Connell MJ and Thynne GS: The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer 58: 603-610, 1986.
17. Zamcheck N: The present status of CEA in diagnosis, prognosis, and evaluation of therapy. Cancer 36: 2460-2468, 1975.
18. Martin EW Jr, James KK, Hurtubise PE, Catalano P and Minton JP: The use of CEA as an early indicator for gastrointestinal tumor recurrence and second-look procedures. Cancer 39: 440-446, 1977.
19. Cooper MJ, Mackie CR, Skinner DB and Moossa AR: A reappraisal of the value of carcinoembryonic antigen in the management of patients with various neoplasms. Br J Surg 66: 120-123, 1979.
20. Steele G Jr, Ellenberg S, Ramming K, O'Connell M, Moertel C, Lessner H, Bruckner H, Horton J, Schein P, Zamcheck N, Novak J and Holyoke ED: CEA monitoring among patients in multi-institutional adjuvant G.I. therapy protocols. Ann Surg 196: 162-169, 1982.
21. Barillari P, Ramacciato G, de Angelis R, Gozzo P, Aurello P, Indinnimeo M, Valabrega S, D'Angelo F and Fegiz G: The role of CEA, TPA and CA 19-9 in the early detection of recurrent colorectal cancer. Int J Colorectal Dis 4: 230-233, 1989.
22. Koprowski H, Herlyn M, Steplewski Z and Sears HF: Specific antigen in serum of patients with colon carcinoma. Science 212: 53-55, 1981.
23. Kuusela P, Jalanko H, Roberts P, Sipponen P, Mecklin JP, Pitkänen R and Mäkelä O: Comparison of CA 19-9 and carcinoembryonic antigen (CEA) levels in the serum of patients with colorectal diseases. Br J Cancer 49: 135-139, 1984.
24. Filella X, Molina R, Grau JJ, Piqué JM, Garcia-Valdecasas JC, Astudillo E, Biete A, Bordas JM, Novell A, Campo E and Ballesta AM: Prognostic value of CA 19.9 levels in colorectal cancer. Ann Surg 216: 55-59, 1992.
25. Kouri M, Pyrhönen S and Kuusela P: Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma. J Surg Oncol 49: 78-85, 1992.
26. Nakayama T, Watanabe M, Teramoto T and Kitajima M: CA19-9 as a predictor of recurrence in patients with colorectal cancer. J Surg Oncol 66: 238-243, 1997.
27. Japanese Society for Cancer of the Colon and Rectum: Japanese classification of colorectal carcinoma. 1st English edition. Kanehara Co., Ltd., Tokyo, 1997.
28. Sobin LH and Wittekind CH: UICC TNM classification of malignant tumors. 5th edition. John Wiley & Sons, Inc., New York, 1997.
29. Jaeck D, Bachellier P, Guiguet M, Boudjema K, Vaillant JC, Balladur P and Nordlinger B: Long-term survival following resection of colorectal hepatic metastases. Association Française de Chirurgie. Br J Surg 84: 977-980, 1997.
30. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghémard O, Levi F and Bismuth H: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240: 644-658, 2004.
31. Ishizuka D, Shirai Y, Sakai Y and Hatakeyama K: Colorectal carcinoma liver metastases: clinical significance of preoperative measurement of serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels. Int J Colorectal Dis 16: 32-37, 2001.
32. Hotta T, Takifuji K, Uchiyama K, Yokoyama S, Matsuda K, Higashiguchi T, Tominaga T, Oku Y, Nasu T and Yamaue H: Potential predictors of survival after surgery for colorectal cancer patients with synchronous unresectable liver metastases. Oncol Rep 16: 1369-1374, 2006.
33. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914, 2000.
34. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047, 2000.
35. De Gramont A, Vignoud J, Tournigand C, Louvet C, André T, Varette C, Raymond E, Moreau S, Le Bail N and Krulik M: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33: 214-219, 1997.
36. Poston GJ: The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. Eur J Surg Oncol 31: 325-330, 2005.